Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance

Abstract

In the original article, in Section 3.1.1, the term "carbapenemases" was associated with Class C β-lactamases instead of Class B β-lactamases in two sentences (Page 10762). In Table 2 (Pages 10764−10765), AmpC was given as an example of Class D noncarbapenemases instead of Class C noncarbapenemases. These small mistakes due to oversight have been rectified below. The authors apologize for the error.

A standardized nomenclature for resistance-modifying agents in the Comprehensive Antibiotic Resistance Database

“…Other than well-known β-lactamase inhibitors (BLIs), until recently, resistance-modifying agents (RMAs) were largely overlooked by CARD’s curators. These agents, also commonly called adjuvants, are molecules that do not exhibit direct or sufficiently efficacious antibiotic activity themselves but rather increase or rescue susceptibility to bona fide antimicrobials in otherwise resistant pathogens ( 2 , 3 ). Herein, we report recent updates to CARD’s Antibiotic Resistance Ontology (ARO) to better classify adjuvants as a major curation effort resulting in the addition of over 60 new molecules to the ARO.…”